Literature DB >> 6982138

Specific detection of circulating DNA:anti-DNA immune complexes in human systemic lupus erythematosus sera using murine monoclonal anti-DNA antibody.

F Tron, J Letarte, M C Roque-Antunes Barreira, P Lesavre.   

Abstract

The presence of DNA-anti-DNA immune complexes in sera from patients with systemic lupus erythematosus (SLE) was investigated by a new solid phase radioimmunoassay (RIA). This assay used murine monoclonal anti-double stranded DNA (dsDNA) antibody to recognize DNA present in the complexes and 125I-rabbit anti-human gamma globulin as a tracer. DNA-anti-DNA immune complexes were found in certain SLE sera but not in sera from patients with other immune complex diseases and from healthy blood donors. The presence of circulating DNA-anti-DNA complexes was associated with low C4 levels. It was not related to the presence of immune complexes detected by the polyethylene glycol assay suggesting either that the assay did not detect all DNA-anti-DNA complexes or that other antigen-antibody systems constitute the major immune complex components in SLE sera. The clinical significance of circulating DNA-anti-DNA complexes in SLE sera as well as the potential use of this solid phase RIA using various monoclonal antibodies to detect specific antigen-antibody systems is discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6982138      PMCID: PMC1536496     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Detection of circulating immune complexes in human sera by simplified assays with polyethylene glycol.

Authors:  M Digeon; M Laver; J Riza; J F Bach
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

2.  Solid-phase enzyme immunoassay or radioimmunoassay for the detection of immune complexes based on their recognition by conglutinin: conglutinin-binding test. A comparative study with 125I-labelled Clq binding and Raji-cell RIA tests.

Authors:  P Casali; A Bossus; N A Carpentier; P H Lambert
Journal:  Clin Exp Immunol       Date:  1977-08       Impact factor: 4.330

3.  Standardization of the chloramine-T method of protein iodination.

Authors:  R Hunter
Journal:  Proc Soc Exp Biol Med       Date:  1970-03

4.  Detection and characterization of DNA-anti-DNA complexes in a patient with systemic lupus erythematosus.

Authors:  C D Bruneau; J P Edmonds; G R Hughes; L Aarden
Journal:  Clin Exp Immunol       Date:  1977-06       Impact factor: 4.330

5.  Relationships between antibodies to native DNA and glomerulonephritis in systemic lupus erythematosus.

Authors:  F Tron; J F Bach
Journal:  Clin Exp Immunol       Date:  1977-06       Impact factor: 4.330

6.  The Raji cell radioimmune assay for detecting immune complexes in human sera.

Authors:  A N Theofilopoulos; C B Wilson; F J Dixon
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

7.  Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus.

Authors:  R H Zubler; G Lange; P H Lambert; P A Miescher
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

8.  Polynucleotide immune complexes in serum and glomeruli of patients with systemic lupus erythematosus.

Authors:  D Koffler; V Agnello; H G Kimkel
Journal:  Am J Pathol       Date:  1974-01       Impact factor: 4.307

9.  DNA:anti-DNA complexes: their detection in systemic lupus erythematosus sera.

Authors:  R J Harbeck; E J Bardana; P F Kohler; R I Carr
Journal:  J Clin Invest       Date:  1973-04       Impact factor: 14.808

10.  Circulating immune complexes in the serum in systemic lupus erythematosus and in carriers of hepatitis B antigen. Quantitation by binding to radiolabeled C1q.

Authors:  U E Nydegger; P H Lambert; H Gerber; P A Miescher
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

View more
  8 in total

1.  Effects of single-stranded DNA on circulating immune complexes in SLE sera detected by C1q solid-phase assay.

Authors:  F Furukawa; K Sekita; E Muso; S Imamura; Y Hamashima
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

Review 2.  Pathogenesis of SLE: immunopathology in man.

Authors:  J R Kalden; T H Winkler; M Herrmann; F Krapf
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

3.  False-negative anti-DNA antibody activity in infantile systemic lupus erythematosus (SLE).

Authors:  S C Jordan; J M Lemire; W Border; R Sakai; R B Ettenger; R N Fine
Journal:  J Clin Immunol       Date:  1984-03       Impact factor: 8.317

4.  Monoclonal anti-DNA antibodies: an approach to studying SLE nephritis.

Authors:  R Cukier; F Tron
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

5.  Administration of monoclonal anti-Sm antibody prolongs the survival and renal function of MRL-lpr/lpr mice.

Authors:  F M Brennan; D G Williams; D Bovill; M R Stocks; R N Maini
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

Review 6.  Anti-DNA antibodies--quintessential biomarkers of SLE.

Authors:  David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2015-11-19       Impact factor: 20.543

Review 7.  An Update on Antibodies to Necleosome Components as Biomarkers of Sistemic Lupus Erythematosus and of Lupus Flares.

Authors:  Gian Marco Ghiggeri; Matteo D'Alessandro; Domenico Bartolomeo; Maria Ludovica Degl'Innocenti; Alberto Magnasco; Francesca Lugani; Marco Prunotto; Maurizio Bruschi
Journal:  Int J Mol Sci       Date:  2019-11-18       Impact factor: 5.923

8.  Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus.

Authors:  Azita Sohrabian; Ioannis Parodis; Nellie Carlströmer-Berthén; Martina Frodlund; Andreas Jönsen; Agneta Zickert; Christopher Sjöwall; Anders A Bengtsson; Iva Gunnarsson; Johan Rönnelid
Journal:  Arthritis Res Ther       Date:  2019-11-29       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.